Hopewell JC - Search Results

1

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.

Hopewell JC, Offer A, Haynes R, Bowman L, Li J, Chen F, Bulbulia R, Lathrop M, Baigent C, Landray MJ, Collins R, Armitage J, Parish S. Hopewell JC, et al. Eur Heart J. 2020 Sep 14;41(35):3336-3342. doi: 10.1093/eurheartj/ehaa574. Eur Heart J. 2020. PMID: 32702748 Free PMC article.

2

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Clarke R, et al. Among authors: hopewell jc. N Engl J Med. 2009 Dec 24;361(26):2518-28. doi: 10.1056/NEJMoa0902604. N Engl J Med. 2009. PMID: 20032323 Free article.

3

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.

Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R; Heart Protection Study Collaborative Group. Hopewell JC, et al. Circ Cardiovasc Genet. 2011 Feb;4(1):68-73. doi: 10.1161/CIRCGENETICS.110.958371. Epub 2011 Jan 20. Circ Cardiovasc Genet. 2011. PMID: 21252144 Clinical Trial.

4

A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.

Coronary Artery Disease (C4D) Genetics Consortium. Coronary Artery Disease (C4D) Genetics Consortium. Nat Genet. 2011 Mar 6;43(4):339-44. doi: 10.1038/ng.782. Nat Genet. 2011. PMID: 21378988

5

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

Hopewell JC, Parish S, Clarke R, Armitage J, Bowman L, Hager J, Lathrop M, Collins R; MRC/BHF Heart Protection Study Collaborative Group. Hopewell JC, et al. J Am Coll Cardiol. 2011 May 17;57(20):2000-7. doi: 10.1016/j.jacc.2011.02.015. Epub 2011 Mar 31. J Am Coll Cardiol. 2011. PMID: 21458191 Free article. Clinical Trial.

6

Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias.

Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, Xu P, Nordestgaard BG, Holm H, Hopewell JC, Saleheen D, Tanaka T, Anand SS, Chambers JC, Kleber ME, Ouwehand WH, Yamada Y, Elbers C, Peters B, Stewart AF, Reilly MM, Thorand B, Yusuf S, Engert JC, Assimes TL, Kooner J, Danesh J, Watkins H, Samani NJ, Collins R, Peto R; MTHFR Studies Collaborative Group. Clarke R, et al. Among authors: hopewell jc. PLoS Med. 2012 Feb;9(2):e1001177. doi: 10.1371/journal.pmed.1001177. Epub 2012 Feb 21. PLoS Med. 2012. PMID: 22363213 Free PMC article.

7

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R; Heart Protection Study Collaborative Group. Parish S, et al. Among authors: hopewell jc. Circulation. 2012 May 22;125(20):2469-78. doi: 10.1161/CIRCULATIONAHA.111.073684. Epub 2012 Apr 26. Circulation. 2012. PMID: 22539783 Clinical Trial.

8

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, Armitage J, Collins R; MRC/BHF Heart Protection Study Collaborative Group. Hopewell JC, et al. Eur Heart J. 2013 Apr;34(13):982-92. doi: 10.1093/eurheartj/ehs344. Epub 2012 Oct 24. Eur Heart J. 2013. PMID: 23100282 Free PMC article. Clinical Trial.

9

Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.

Li J, Chen YP, Li X, Armitage J, Feng F, Liu JM, Gao Y, Zhang HB, Zhang D, Hundei WB, Chen ZM, Chen F, Hopewell JC, Valdes-Marquez E, Landray M, Jiang LX; HPS2-THRIVE Collaborative Group. Li J, et al. Among authors: hopewell jc. Chin Med J (Engl). 2012 Dec;125(24):4361-7. Chin Med J (Engl). 2012. PMID: 23253702

10

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

HPS2-THRIVE Collaborative Group. HPS2-THRIVE Collaborative Group. Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26. Eur Heart J. 2013. PMID: 23444397 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page